Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company, is preparing for a clinical trial event by the end of this year.
The company's lead drug candidate is Onvansertib, a PLK1 inhibitor, which in combination with standard-of-care (SoC) therapeutics is targeting indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com